Publisher： Adis International
ISSN： 1173-8324
Source： Inpharma, Vol.1, Iss.1654, 2008-01, pp. : 4-4
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
First-line sunitinib cost-effective alternative to interferon-α in renal cancer
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 561, 2008-01 ,pp. :
Access to resources
Recommend
Sunitinib cost effective for renal cancer
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 532, 2007-01 ,pp. :
By Ravasio Roberto Ortega Cinzia Sabbatini Roberto Porta Camillo
Clinical Drug Investigation, Vol. 31, Iss. 7, 2011-07 ,pp. :
Sorafenib a cost-effective option in renal cancer
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 516, 2006-01 ,pp. :
Gatifloxacin a cost-effective alternative for CAP
Inpharma, Vol. 1, Iss. 1298, 2001-01 ,pp. :